Department of Health vs. Phil Pharma Wealth, Inc.

An unincorporated government agency performing governmental or sovereign functions is immune from suit without its consent, and a complaint that seeks to impose a financial charge against the State must be dismissed. Public officials sued for acts performed in the discharge of official duties share this immunity unless they are shown to have acted ultra vires or with bad faith, and the judgment would require the State to take an affirmative act such as appropriating funds to satisfy an award of damages.

The DOH, through successive administrative orders, established an accreditation system for pharmaceutical suppliers to the government. PPI, an accredited supplier, was found by the Bureau of Food and Drugs (BFAD) to be distributing substandard and violative drug products. Following a directive to explain the adverse findings, PPI failed to file a timely substantive response. The DOH Undersecretary suspended PPI’s accreditation for two years. PPI responded with a complaint for damages and nullification of the DOH orders, asserting that the suspension was imposed without the notice and hearing required under Section 26(d) of RA 3720 as amended by EO 175, and that the officials acted beyond their authority. The core question was whether the suit could proceed or was barred by the doctrine of state immunity.

• DOH Accreditation Framework: On December 22, 1998, DOH AO No. 27 s. 1998 set guidelines for accrediting government pharmaceutical suppliers. AO No. 10 s. 2000 (Secretary Romualdez) reduced the accreditation period to two years and provided that accreditation could be recalled, suspended, or revoked after due deliberation and proper notice. AO No. 66 s. 2000 strengthened this to require due deliberation, hearing, and notice. Memorandum No. 171-C established a list of sanctions for adverse findings. AO No. 14 s. 2001 (Secretary Dayrit) later provided new accreditation guidelines and empowered the Accreditation Committee to suspend or revoke accreditation after deliberation and notice without need of a hearing.
• Adverse Findings and Meeting: BFAD issued a “Report on Violative Products” finding that several of PPI’s drug products were unfit for human consumption. On October 27, 2000, Undersecretary Galon convened 24 accredited drug companies, including PPI, distributed the report, and directed them to submit their written explanations within 10 days, or by November 6, 2000.
• PPI’s Response and Suspension: PPI did not meet the deadline. It sent a letter dated November 13, 2000 informing Undersecretary Galon that it had referred the matter to its lawyers to prepare an appropriate reply, without indicating when the reply would be submitted or requesting an extension. On November 23, 2000, Undersecretary Galon found the explanation untenable and suspended PPI’s accreditation effective immediately for two years.
• PPI’s Suit: PPI filed a complaint (later amended) to declare AO 10, Memorandum No. 171-C, the suspension order, and AO 14 null and void for being contrary to Section 26(d) of RA 3720 as amended by EO 175, which vests the power to act on violative products in the BFAD Director with notice and hearing. PPI claimed denial of administrative due process and prayed for ₱5 million moral damages, ₱1 million exemplary damages, ₱1 million attorney’s fees, and costs of suit, plus injunctive relief.

• Suit Against the State: Petitioners argued that the complaint was a suit against the State because it sought damages from the DOH, which would require an appropriation from the national treasury. The State had not consented to be sued; therefore, the case must be dismissed.
• Official Capacity: Petitioners maintained that Secretaries Romualdez and Dayrit and Undersecretary Galon were sued for acts performed within their official functions. The issuances and the suspension were implemented to protect public health and were well within the DOH’s mandate and the Secretary’s rule-making authority under RA 3720.

• Personal Capacity Suit: PPI argued that the complaint was directed against the individual officials in their personal capacities for acts done beyond the scope of their authority — specifically, for usurping the BFAD Director’s statutory power under Section 26(d) of RA 3720. Consequently, state immunity did not bar the suit, and the CA correctly remanded the case for trial.

• State Immunity: Whether Civil Case No. 68200 should be dismissed on the ground that it is a suit against the State without its consent.

• State Immunity: The complaint was ordered dismissed. The DOH is an unincorporated agency of the government performing sovereign or governmental functions. Absent express or implied consent to be sued — neither of which was present — it enjoys immunity from suit. PPI’s complaint expressly sought to hold the DOH solidarily liable for moral, exemplary, and actual damages, which would directly impose a financial charge against the State and require an appropriation. The individual officials were sued for acts performed in the discharge of their official duties: the Health Secretary is authorized under RA 3720 to issue implementing rules and regulations, and the Undersecretary has statutory supervisory authority over offices under the DOH. Thus, the issuance of the assailed orders and the suspension of PPI’s accreditation were not ultra vires. Nor was there a showing of bad faith; PPI was afforded due process when given the opportunity to submit its explanation within 10 days but failed to do so. Because any adverse judgment would necessitate state action to satisfy the award, the suit must be regarded as one against the State, and the defense of non-suability properly attaches.

• State Immunity from Suit — The State may not be sued without its consent. Consent may be express (by general or special law) or implied (when the State enters into a contract in its proprietary capacity or itself commences litigation). Waivers of immunity are construed strictissimi juris.
• Immunity of Unincorporated Government Agencies — An unincorporated government agency without separate juridical personality performing governmental or sovereign functions is immune from suit. If the function is essentially proprietary, immunity does not attach.
• Immunity of Public Officials — Public officials are shielded from suit for acts done in the performance of official functions, provided the acts are not ultra vires or performed with bad faith. The determinative test is whether the acts were within the scope of official authority and whether a judgment would result in a financial charge against the State, requiring an appropriation.
• Administrative Due Process — The essence of due process in administrative proceedings is the opportunity to explain one’s side or seek reconsideration. Where a party is afforded that opportunity but fails to avail of it, no denial of due process occurs.

• “The basic postulate enshrined in the constitution that ‘[t]he State may not be sued without its consent,’ reflects nothing less than a recognition of the sovereign character of the State and an express affirmation of the unwritten rule effectively insulating it from the jurisdiction of courts.”
• “An unincorporated government agency without any separate juridical personality of its own enjoys immunity from suit because it is invested with an inherent power of sovereignty. … The immunity has been upheld in favor of the former because its function is governmental or incidental to such function; it has not been upheld in favor of the latter whose function was not in pursuit of a necessary function of government but was essentially a business.”
• “The suability of a government official depends on whether the official concerned was acting within his official or jurisdictional capacity, and whether the acts done in the performance of official functions will result in a charge or financial liability against the government.”
• “[T]he rule is that if the judgment against such officials will require the state itself to perform an affirmative act to satisfy the same, such as the appropriation of the amount needed to pay the damages awarded against them, the suit must be regarded as against the state x x x.”
• “The essence of due process in administrative proceedings is the opportunity to explain one’s side or seek a reconsideration of the action or ruling complained of. … What is offensive to due process is the denial of the opportunity to be heard.”

• Department of Agriculture v. National Labor Relations Commission, G.R. No. 104269, November 11, 1993, 227 SCRA 693 — Cited as the foundational exposition of the doctrine of non-suability and the distinction between express and implied consent.
• Air Transportation Office v. Ramos, G.R. No. 159402, February 23, 2011, 644 SCRA 36 — Followed for the principle distinguishing between governmental and proprietary functions of unincorporated agencies for immunity purposes.
• United States of America v. Judge Guinto, 261 Phil. 777 (1990) — Relied upon for the rules on implied waiver and the test for when a suit against officials is effectively against the State.
• Department of Health v. Phil Pharmawealth, Inc., 547 Phil. 148 (2007) — Controlling precedent between the same parties, holding that the DOH is an unincorporated agency performing governmental functions and that a damages claim constitutes a charge against the State.
• M.H. Wylie v. Rarang, G.R. No. 74135, May 28, 1992, 209 SCRA 357 — Cited for the exception that public officials may be held personally liable for ultra vires acts or bad faith.
• Flores v. Montemayor, G.R. No. 170146, June 8, 2011, 651 SCRA 396 — Cited for the standard of administrative due process.

• Section 3, Article XVI, 1987 Constitution — Embodies the fundamental rule that the State may not be sued without its consent; applied as the bedrock of the dismissal.
• Section 26(d), Republic Act No. 3720, as amended by Executive Order No. 175 — The provision PPI invoked as vesting exclusive authority in the BFAD Director. The Court implicitly rejected the claim that acting outside this provision rendered the officials’ acts ultra vires, holding instead that the Secretary’s general rule-making power and the Undersecretary’s supervisory authority under the law encompassed the assailed actions.
• Section 4, Republic Act No. 3720 — Establishes the BFAD as an office under the Health Secretary, supporting the officials’ authority.
• Section 12, Chapter 3, Title IX, Book IV, Administrative Code of 1987 — Grants the Undersecretary supervisory authority over offices under the DOH, cited to confirm that Undersecretary Galon acted within her official capacity.

Associate Justices Antonio T. Carpio (Chairperson), Arturo D. Brion, Diosdado M. Peralta, and Jose Portugal Perez. Chief Justice Maria Lourdes P. A. Sereno certified the decision.